News & Videos - VOLITIONRX LTD. - Page 2

Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland PR Newswire HENDERSON, Nev., Nov. 6, 2023 HENDERSON, Nev. , Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland . VPG is the first-to-market diagnostic laboratory in the UK and...

Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland PR Newswire HENDERSON, Nev., Nov. 6, 2023 HENDERSON, Nev. , Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland . VPG is the first-to-market diagnostic laboratory in the UK and...

VolitionRx (NYSE: VNRX) and Edison recently hosted a webinar, during which the company provided insights into its progress in ......

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer PR Newswire HENDERSON, Nev., Oct. 23, 2023 HENDERSON, Nev. , Oct. 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology. In early-stage cancer, it is difficult to detect cancer-derived...

Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock PR Newswire HENDERSON, Nev., Oct. 19, 2023 HENDERSON, Nev. , Oct. 19, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a clinical paper 1 which shows that Volition's Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis...

Volition Presents Three Cancer Detection Abstracts at ESMO 2023 PR Newswire HENDERSON, Nev., Oct. 16, 2023 HENDERSON, Nev. , Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the annual congress of the European Society for Medical Oncology. Dr. Jake Micallef , Chief Scientific Officer at Volition, said: "We are delighted to be attending ESMO 2023 and have the...

Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis PR Newswire HENDERSON, Nev., Oct. 13, 2023 HENDERSON, Nev. , Oct. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report summarising key themes from its recent Key Opinion Leader ("KOL") roundtable on sepsis management. Remi Rabeuf , Lifecycle Leader at Volition, said: "We were delighted to bring together some of the world's leading...

Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar PR Newswire HENDERSON, Nev., Oct. 2, 2023 HENDERSON, Nev. , Oct. 2, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21 st at ESMO 2023, the annual congress of the European Society for Medical Oncology. The webinar takes place on Thursday, October 26 th...

Volition Hosts Key Opinion Leader Roundtable on Sepsis Management PR Newswire HENDERSON, Nev., Sept. 13, 2023 HENDERSON, Nev. , Sept. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a Key Opinion Leader ("KOL") roundtable discussion in Athens this weekend, bringing together world-renowned experts in sepsis. Chaired by Professor Djillali Annane , Professor of Medicine at University Paris Saclay-UVSQ , and one of the...

VolitionRx (NYSE American: VNRX) is a multinational epigenetics company that applies its Nucleosomics platform through its ......

VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update PR Newswire HENDERSON, Nev., Aug. 14, 2023 Conference call to discuss financial and operational results scheduled for Tuesday, August 15 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , Aug. 14, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2023 . Volition management will host a...

VolitionRx Limited Schedules Second Quarter 2023 Earnings Conference Call and Business Update PR Newswire HENDERSON, Nev, Aug. 9, 2023 Conference call to take place on Tuesday, August 15 at 8:30 a.m. Eastern Time HENDERSON, Nev , Aug. 9, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, August 15 at 8.30 a.m. Eastern Time to discuss its financial and operating results for the second quarter 2023, in addition to...

VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters PR Newswire HENDERSON, Nev., June 23, 2023 HENDERSON, Nev. , June 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross...

VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock PR Newswire HENDERSON, Nev., June 5, 2023 HENDERSON, Nev. , June 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million , before deducting...

VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock PR Newswire HENDERSON, Nev., June 1, 2023 HENDERSON, Nev. , June 1, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share. The gross proceeds to Volition from the offering,...

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock PR Newswire HENDERSON, Nev., May 31, 2023 HENDERSON, Nev. , May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock. In addition, Volition intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the...

Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring PR Newswire HENDERSON, Nev., May 11, 2023 HENDERSON, Nev. , May 11, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic cancers. The...

VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update PR Newswire HENDERSON, Nev., May 10, 2023 Conference call to discuss financial and operational results scheduled for Thursday, May 11 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. , May 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2023 . Volition management will host a conference...

VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update PR Newswire HENDERSON, Nev., May 5, 2023 Conference call to take place on Thursday May 11 at 08:30 a.m. Eastern Time Capital Markets Day - Thursday May 11 at 2:00 p.m. Eastern Time HENDERSON, Nev. , May 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday May 11 at 08.30 a.m. Eastern Time to discuss its financial and...

VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11. PR Newswire HENDERSON, Nev., April 26, 2023 HENDERSON, Nev. , April 26, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company is hosting a Capital Markets Day in a hybrid format (in-person and live-webcast) on Thursday, May 11, 2023 , at 2 p.m. U.S. Eastern Time. Volition's executive team will be joined by Key Opinion Leaders: Dr. Andy Retter (Intensive Care...